DNLI Denali Therapeutics Inc. Stock Quote

DNLI [NASD]

Index	-	P/E	556.00	EPS (ttm)	0.14	Insider Own	2.60%	Shs Outstand	120.89M	Perf Week	4.48%
Market Cap	9.00B	Forward P/E	-	EPS next Y	-2.06	Insider Trans	-49.67%	Shs Float	100.78M	Perf Month	45.18%
Income	57.90M	PEG	-	EPS next Q	-0.40	Inst Own	76.90%	Short Float	5.67%	Perf Quarter	21.04%
Sales	340.00M	P/S	26.47	EPS this Y	130.50%	Inst Trans	-0.26%	Short Ratio	11.20	Perf Half Y	-5.26%
Book/sh	9.14	P/B	8.21	EPS next Y	-12.60%	ROA	4.80%	Target Price	78.40	Perf Year	203.76%
Cash/sh	11.78	P/C	6.37	EPS next 5Y	-	ROE	6.40%	52W Range	22.36 - 93.94	Perf YTD	-10.39%
Dividend	-	P/FCF	21.67	EPS past 5Y	38.50%	ROI	5.40%	52W High	-22.32%	Beta	1.89
Dividend %	-	Quick Ratio	26.20	Sales past 5Y	-	Gross Margin	-	52W Low	226.34%	ATR	3.26
Employees	311	Current Ratio	26.20	Sales Q/Q	119.40%	Oper. Margin	15.10%	RSI (14)	67.92	Volatility	3.74% 5.22%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-4.50%	Profit Margin	17.00%	Rel Volume	0.40	Prev Close	75.06
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	0.00%	Avg Volume	510.03K	Price	72.97
Recom	2.10	SMA20	12.35%	SMA50	23.50%	SMA200	23.86%	Volume	161,329	Change	-2.78%

May-18-21

Initiated

UBS

Buy

$70

Feb-26-21

Reiterated

H.C. Wainwright

Buy

$80 → $95

Feb-10-21

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$105

Nov-11-20

Reiterated

H.C. Wainwright

Buy

$65 → $80

Oct-16-20

Downgrade

BTIG Research

Buy → Neutral

Sep-14-20

Resumed

JP Morgan

Overweight

$35

Aug-20-20

Reiterated

H.C. Wainwright

Buy

$28 → $45

Mar-13-20

Upgrade

Evercore ISI

In-line → Outperform

$20

Feb-28-20

Upgrade

Wedbush

Neutral → Outperform

$24

Feb-24-20

Initiated

Jefferies

Buy

$35

Feb-19-20

Initiated

Stifel

Hold

$26

Jan-27-20

Upgrade

Goldman

Neutral → Buy

$20 → $37

Sep-26-19

Initiated

Wedbush

Neutral

$19

Sep-13-19

Initiated

Nomura

Buy

Aug-09-19

Initiated

BTIG Research

Buy

$30

Jun-26-19

Initiated

H.C. Wainwright

Buy

$28

Nov-15-18

Initiated

Cantor Fitzgerald

Overweight

$25

Nov-12-18

Initiated

Janney

Buy

Mar-12-18

Downgrade

Evercore ISI

Outperform → In-line

Jan-02-18

Initiated

Morgan Stanley

Overweight

Jun-15-21 08:43AM	Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming? Zacks
Jun-14-21 07:51PM	Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative PR Newswire
Jun-02-21 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report? Zacks
May-25-21 06:00AM	Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire +5.04%
May-19-21 09:01AM	Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire
May-12-21 09:32AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson Insider Monkey -6.09%
May-10-21 03:57PM	Biden's Budget May Boost These 3 Biotechs Motley Fool -5.03%
May-07-21 01:27AM	Bearish: Analysts Just Cut Their Denali Therapeutics Inc. (NASDAQ:DNLI) Revenue and EPS estimates Simply Wall St.
May-04-21 01:46PM	Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y Zacks
May-03-21 09:45AM	Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:30AM	Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights GlobeNewswire
06:46AM	Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End Benzinga
May-01-21 09:00AM	Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinsons Disease GlobeNewswire
Apr-30-21 01:32PM	Is Denali Therapeutics Inc. (DNLI) A Smart Long-Term Buy? Insider Monkey
Apr-29-21 12:34PM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Mar-30-21 01:23PM	Replay: Investing in Alzheimers Treatment Jupiter Orphan Therapeutics CEO Joins Fireside Chat IPO-Edge.com
09:30AM	Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer PR Newswire
Mar-27-21 11:31AM	Denali Therapeutics Inc. (DNLI) Down 12.3% Since Last Earnings Report: Can It Rebound? Zacks
Mar-23-21 01:53PM	Investing in Alzheimers Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30 IPO-Edge.com -5.38%
Mar-19-21 09:45AM	Is Denali Therapeutics (DNLI) A Smart Long-Term Buy? Insider Monkey
Mar-12-21 11:54AM	7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines InvestorPlace
Mar-11-21 03:38PM	Why Denali Therapeutics Stock Popped Today Motley Fool +12.27%
08:30AM	Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II) GlobeNewswire
Mar-01-21 05:11PM	Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal Zacks -9.94%
Feb-25-21 04:01PM	Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights GlobeNewswire -5.63%
Feb-16-21 04:16PM	Cassava Stock Pops Again; Can It Take On Biogen In Alzheimer's Drugs? Investor's Business Daily -6.03%
Feb-12-21 08:54AM	Denali's Enzyme Replacement Therapy Shows Encouraging Biomarker Effects In Early-Stage Hunter Syndrome Study Benzinga
07:30AM	Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II) GlobeNewswire
Feb-11-21 01:27AM	We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely Simply Wall St. -5.32%
Feb-05-21 09:00AM	Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium GlobeNewswire
Jan-11-21 08:30AM	Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors GlobeNewswire
Jan-08-21 08:30AM	Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration GlobeNewswire +8.32%
Dec-23-20 03:33PM	Why MongoDB, Blink Charging, Ampio Pharmaceuticals, and Denali Therapeutics Stocks Tanked Today Motley Fool -5.87%
Dec-22-20 09:48AM	5 Medical Outperformers That Might Lose Steam in 2021 Zacks
Nov-18-20 09:36AM	3 Best Biotech Stocks to Buy in November Motley Fool -6.91%
Nov-13-20 08:35AM	Denali Therapeutics (DNLI) Surges: Stock Moves 5.7% Higher Zacks -6.82%
06:06AM	Industry Analysts Just Made A Massive Upgrade To Their Denali Therapeutics Inc. (NASDAQ:DNLI) Revenue Forecasts Simply Wall St.
Nov-12-20 11:18AM	Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals? Motley Fool +5.70%
Nov-10-20 07:30AM	Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II) GlobeNewswire +7.51%
Nov-05-20 04:01PM	Denali Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Oct-21-20 02:00PM	Biogen Inc (BIIB) Q3 2020 Earnings Call Transcript Motley Fool
Oct-18-20 11:00AM	Goldman Sachs: 2 Stocks That Could Climb Over 90% TipRanks
Oct-15-20 08:00AM	Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier (BBB) TV Platform at Virtual R&D Day Today GlobeNewswire
Oct-07-20 08:30AM	Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen GlobeNewswire
Oct-05-20 12:01PM	Hedge Funds Are Crazy About Denali Therapeutics Inc. (DNLI) Insider Monkey
Sep-30-20 09:00AM	Denali Therapeutics to Host Webinar on Transporting Biotherapeutics Across the Blood-Brain Barrier GlobeNewswire
Sep-24-20 11:46AM	25 Easiest Trivia Questions For Seniors With Dementia Insider Monkey
Aug-18-20 11:37AM	Loss-Making Denali Therapeutics Inc. (NASDAQ:DNLI) Set To Breakeven Simply Wall St.
Aug-07-20 05:45PM	Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:30PM	Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Aug-06-20 04:19PM	Biogen, Denali Announce Billion-Dollar Collaboration On Parkinson's Treatment Investor's Business Daily +36.23%
09:13AM	Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration MarketWatch
08:07AM	Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinsons Patients GlobeNewswire
Jul-29-20 09:00AM	Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients GlobeNewswire
Jul-28-20 12:32PM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-07-20 08:00AM	Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing PR Newswire
Jun-28-20 07:06PM	Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI) Insider Monkey
Jun-10-20 02:03PM	Sanofi and Denali Halt Clinical Trials of Alzheimer Drug Motley Fool
02:51AM	Denali Drops 7% In After-Market On Halt Of DNL747 Drug Study SmarterAnalyst
Jun-09-20 04:30PM	Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi GlobeNewswire
May-28-20 11:21AM	Venture Funding of Drug Startups Down, But Not Out GuruFocus.com
08:00AM	Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity PR Newswire
May-27-20 04:30PM	Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine GlobeNewswire +5.67%
May-21-20 12:00PM	What Makes Denali Therapeutics Inc. (DNLI) a New Buy Stock Zacks
May-10-20 09:18AM	Analyst Estimates: Here's What Brokers Think Of Denali Therapeutics Inc. (NASDAQ:DNLI) After Its First-Quarter Report Simply Wall St.
May-07-20 08:20PM	Denali Therapeutics Inc (DNLI) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.58%
04:30PM	Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update GlobeNewswire
May-06-20 12:30PM	Analysts Estimate Denali Therapeutics Inc.(DNLI) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-15-20 02:49PM	Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock? Insider Monkey
Apr-09-20 06:08PM	Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals
Apr-02-20 04:30PM	Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic GlobeNewswire +8.93%
Feb-29-20 08:47AM	Denali Therapeutics Inc. Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Feb-27-20 05:55PM	Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Lags Revenue Estimates Zacks -12.07%
04:30PM	Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights GlobeNewswire
Feb-17-20 10:06AM	3 Stocks That Are Way More Expensive Than Tesla GuruFocus.com
Feb-14-20 03:00PM	Denali Therapeutics chief medical officer sets a cultural standard American City Business Journals
12:00PM	Denali Therapeutics Inc. (DNLI) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Feb-07-20 11:30AM	Has Denali Therapeutics (DNLI) Outpaced Other Medical Stocks This Year? Zacks
Feb-03-20 11:11AM	Aimmune's Palforzia Wins FDA Approval for Peanut Allergy Zacks
Jan-31-20 08:42PM	Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
03:02PM	Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales Zacks
09:52AM	Moving Average Crossover Alert: Denali Therapeutics Zacks
Jan-30-20 11:10AM	Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks -6.81%
10:54AM	Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 35% TipRanks
10:15AM	Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Jan-29-20 11:11AM	Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal Zacks
10:06AM	Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation Zacks
Jan-28-20 08:58PM	Denali Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -11.22%
11:14AM	AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study Zacks
Jan-27-20 04:10PM	Denali Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire +13.51%
Jan-23-20 09:34AM	Axsome (AXSM) Completes Patient Randomization in TRD Study Zacks +6.41%
Jan-22-20 10:00AM	Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance Zacks +6.32%
Jan-16-20 09:52AM	Novavax Rises on Fast Track Designation to Influenza Vaccine Zacks +7.41%
Jan-15-20 09:36AM	Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results Zacks -9.48%
06:11AM	Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks
Jan-14-20 10:03AM	Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View Zacks +29.35%
09:00AM	Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinsons Disease GlobeNewswire
Dec-31-19 11:01AM	Denali Therapeutics (NASDAQ:DNLI) Is In A Strong Position To Grow Its Business Simply Wall St.
Dec-19-19 08:00AM	Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire +8.11%
Dec-17-19 04:06PM	Denali Therapeutics Inc. (DNLI): Are Hedge Funds Right About This Stock? Insider Monkey

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tessier-Lavigne Marc	Director	Jun 07	Option Exercise	18.70	94,378	1,765,275	2,638,748	Jun 08 05:10 PM
Tessier-Lavigne Marc	Director	Jun 07	Sale	70.35	94,378	6,639,523	2,544,370	Jun 08 05:10 PM
Schuth Alexander O.	COO and Secretary	Jun 04	Sale	64.55	10,000	645,500	501,582	Jun 08 05:10 PM
Schenkein David P	Director	Jun 01	Option Exercise	0.00	3,253	0	3,253	Jun 03 08:57 PM
NELSEN ROBERT	Director	Jun 01	Option Exercise	0.00	3,253	0	10,358	Jun 03 08:55 PM
Klein Peter S	Director	Jun 01	Option Exercise	0.00	3,253	0	3,253	Jun 03 08:54 PM
FLATLEY JAY T	Director	Jun 01	Option Exercise	0.00	3,253	0	328,253	Jun 03 08:53 PM
Cook Jennifer E.	Director	Jun 01	Option Exercise	0.00	3,253	0	3,253	Jun 03 08:52 PM
Cole Douglas G.	Director	Jun 01	Option Exercise	0.00	3,253	0	3,253	Jun 03 08:51 PM
Watts Ryan J.	President and CEO	Jun 01	Sale	61.40	18,333	1,125,648	2,210,742	Jun 03 08:08 PM
SATO VICKI L	Director	May 26	Sale	65.37	1,666	108,911	134,089	May 28 04:03 PM
Tessier-Lavigne Marc	Director	May 24	Sale	60.02	8,806	528,580	2,542,296	May 24 08:05 PM
Tessier-Lavigne Marc	Director	May 21	Sale	60.13	37,957	2,282,468	2,551,102	May 24 08:05 PM
Schuth Alexander O.	COO and Secretary	May 04	Sale	55.49	10,000	554,864	511,582	May 06 06:50 PM
SATO VICKI L	Director	Apr 28	Sale	62.15	1,666	103,538	135,755	Apr 30 05:07 PM
Schuth Alexander O.	COO and Secretary	Apr 05	Sale	56.09	10,000	560,901	521,582	Apr 06 08:39 PM
Tessier-Lavigne Marc	Director	Apr 01	Sale	56.62	50,000	2,831,071	2,592,296	Apr 05 04:10 PM
Watts Ryan J.	President and CEO	Apr 01	Sale	56.60	18,334	1,037,684	2,247,408	Apr 05 04:09 PM
Ho Carole	Chief Medical Officer	Mar 29	Sale	54.62	2,822	154,126	162,319	Mar 31 06:30 PM
Krognes Steve E.	CFO and Treasurer	Mar 15	Sale	61.89	50,000	3,094,563	850,000	Mar 16 07:16 PM
Schuth Alexander O.	COO and Secretary	Mar 04	Sale	61.02	10,000	610,171	531,582	Mar 04 06:38 PM
SATO VICKI L	Director	Mar 03	Sale	61.61	1,666	102,641	139,087	Mar 04 06:04 PM
Ho Carole	Chief Medical Officer	Mar 01	Sale	66.38	7,092	470,741	165,141	Mar 03 04:21 PM
Tessier-Lavigne Marc	Director	Mar 01	Sale	66.22	100,000	6,622,207	2,642,296	Mar 03 04:20 PM
Watts Ryan J.	President and CEO	Mar 01	Sale	66.35	18,334	1,216,551	2,305,742	Mar 03 04:19 PM
Krognes Steve E.	CFO and Treasurer	Feb 16	Sale	65.09	50,000	3,254,710	900,000	Feb 18 06:12 PM
BRATTON DOUGLAS K	10% Owner	Feb 12	Sale	65.00	2,216,798	144,091,870	9,984,836	Feb 17 08:39 PM
Ho Carole	Chief Medical Officer	Feb 11	Sale	70.33	3,156	221,972	172,233	Feb 16 07:43 PM
Schuth Alexander O.	COO and Secretary	Feb 11	Sale	70.35	3,047	214,341	541,582	Feb 16 07:43 PM
Krognes Steve E.	CFO and Treasurer	Feb 11	Sale	70.34	3,035	213,480	97,587	Feb 16 07:42 PM
Watts Ryan J.	President and CEO	Feb 11	Sale	70.30	9,473	665,984	2,324,076	Feb 16 07:40 PM
Schuth Alexander O.	COO and Secretary	Feb 09	Sale	74.80	1,468	109,809	537,344	Feb 11 07:13 PM
Krognes Steve E.	CFO and Treasurer	Feb 09	Sale	74.68	1,448	108,135	12,979	Feb 11 07:11 PM
Ho Carole	Chief Medical Officer	Feb 09	Sale	74.68	1,470	109,785	167,921	Feb 11 07:10 PM
Watts Ryan J.	President and CEO	Feb 09	Sale	73.79	5,112	377,211	2,313,853	Feb 10 07:40 PM
Watts Ryan J.	President and CEO	Feb 08	Option Exercise	0.00	14,316	0	2,318,965	Feb 10 07:40 PM
Schuth Alexander O.	COO and Secretary	Feb 07	Option Exercise	0.00	4,250	0	538,812	Feb 11 07:13 PM
Krognes Steve E.	CFO and Treasurer	Feb 07	Option Exercise	0.00	4,250	0	14,427	Feb 11 07:11 PM
Ho Carole	Chief Medical Officer	Feb 07	Option Exercise	0.00	4,250	0	169,391	Feb 11 07:10 PM
Schuth Alexander O.	COO and Secretary	Feb 04	Sale	67.84	10,000	678,361	534,562	Feb 05 04:44 PM
Watts Ryan J.	President and CEO	Feb 01	Sale	68.44	18,334	1,254,819	2,304,649	Feb 02 09:21 PM
Krognes Steve E.	CFO and Treasurer	Jan 15	Sale	71.45	50,000	3,572,556	950,000	Jan 20 06:46 PM
Schuth Alexander O.	COO and Secretary	Jan 04	Sale	74.95	70,000	5,246,408	544,562	Jan 06 06:50 PM
Watts Ryan J.	President and CEO	Jan 04	Sale	74.96	88,334	6,621,782	2,322,978	Jan 06 06:49 PM
Schenkein David P	Director	Dec 21	Sale	90.01	5,000	450,027	26,232	Dec 23 09:52 PM
Schenkein David P	Director	Dec 21	Sale	90.06	25,000	2,251,555	0	Dec 23 09:52 PM
BRATTON DOUGLAS K	10% Owner	Dec 14	Sale	80.38	17,825	1,432,842	383,411	Dec 15 04:47 PM
BRATTON DOUGLAS K	10% Owner	Dec 11	Sale	80.05	46,799	3,746,442	401,236	Dec 15 04:47 PM
Schenkein David P	Director	Nov 12	Sale	70.05	30,000	2,101,590	25,000	Nov 13 05:13 PM
Schenkein David P	Director	Nov 10	Sale	60.03	10,000	600,310	55,000	Nov 12 04:21 PM
Schenkein David P	Director	Nov 04	Sale	50.18	10,000	501,830	65,000	Nov 06 05:53 PM
Ho Carole	Chief Medical Officer	Oct 09	Option Exercise	5.28	30,000	158,400	196,617	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Oct 09	Sale	41.22	30,000	1,236,614	166,617	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Oct 08	Option Exercise	5.28	22,906	120,944	189,523	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Oct 08	Sale	40.12	22,906	918,989	166,617	Oct 13 06:45 PM
Ho Carole	Chief Medical Officer	Sep 10	Sale	31.00	3,689	114,359	165,141	Sep 14 09:38 PM
BRATTON DOUGLAS K	10% Owner	Aug 12	Sale	31.65	1,443,247	45,678,768	12,201,634	Aug 14 04:50 PM
BRATTON DOUGLAS K	10% Owner	Jun 30	Sale	24.01	45,345	1,088,601	448,035	Jun 30 07:17 PM
BRATTON DOUGLAS K	10% Owner	Jun 29	Sale	24.01	82,578	1,982,373	493,380	Jun 30 07:17 PM
BRATTON DOUGLAS K	10% Owner	Jun 26	Sale	23.94	122,077	2,922,078	575,958	Jun 30 07:17 PM
BRATTON DOUGLAS K	10% Owner	Jun 23	Sale	25.77	20,024	515,969	698,035	Jun 23 05:41 PM
BRATTON DOUGLAS K	10% Owner	Jun 22	Sale	24.78	90,056	2,231,902	718,059	Jun 23 05:41 PM
BRATTON DOUGLAS K	10% Owner	Jun 19	Sale	24.54	144,920	3,556,503	808,115	Jun 23 05:41 PM
Tessier-Lavigne Marc	Director	Jun 16	Sale	26.10	400,000	10,440,000	2,739,043	Jun 18 09:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience